Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,384JPY
19 Jan 2018
Change (% chg)

¥-6 (-0.47%)
Prev Close
¥1,390
Open
¥1,396
Day's High
¥1,398
Day's Low
¥1,380
Volume
6,939,000
Avg. Vol
7,255,395
52-wk High
¥1,570
52-wk Low
¥1,332

Select another date:

Tue, Jan 9 2018

BRIEF-Astellas Pharma says application of marketing approval for blinatumomab in Japan

* Says it announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct blinatumomab to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia

BRIEF-Astellas acquires Mitobridge under existing collaboration

* SAYS ‍MITOBRIDGE WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF ASTELLAS FOLLOWING CLOSE OF ACQUISITION​ Source text for Eikon: Further company coverage:

Astellas faces U.S. probe over patient assistance charity support

BOSTON Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

Astellas faces U.S. probe over patient assistance charity support

BOSTON, Nov 15 Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

BRIEF-Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin

* Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer

BRIEF-Astellas Pharma completes share repurchase

* Says it completed repurchase of 49.3 million shares of its common stock, for 70 billion yen in total, as of Oct. 31

BRIEF-Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D

* Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​

Fitch Revises Beijing Capital Development's Outlook to Negative, Affirms Rating at 'BBB-'

(The following statement was released by the rating agency) HONG KONG, October 18 (Fitch) Fitch Ratings has revised Beijing Capital Development Holding (Group) Co., Ltd.'s (known by its abbreviated Chinese name Shokai Group) Outlook to Negative from Stable. Shokai Group's Long-Term Foreign-Currency Issuer Default Rating (IDR) has been affirmed at 'BBB-', and its senior unsecured rating and the ratings of all outstanding bonds have also been affirmed at 'BBB-'. A full list of rating actions is at

BRIEF-FDA grants fast track status to Astellas for acute myeloid leukemia drug

* U.S. FDA grants fast track designation to Astellas for development of gilteritinib in relapsed or refractory acute myeloid leukemia Source text for Eikon: Further company coverage:

BRIEF-Astellas and Seattle Genetics initiate trial of enfortumab vedotin for ureter cancer patients

* Astellas and Seattle Genetics initiate pivotal trial of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer

Select another date: